AOPEP and breast cancer: Interestingly, EV‐Apo (50−100 μg/mL) treatment significantly promoted the migration and invasion of breast cancer 4T1 cells in the presence of Raw264.7 macrophages, whereas EV‐alive exhibited minimal effects on that (Figure 1f).